Paxos Medical

Paxos Medical operates at the intersection of medical devices, urology, pelvic health, and neuromodulation. Its focus is relatively specific: UnderControl™ is designed for underactive bladder, a condition for which the company aims to restore voluntary voiding and reduce reliance on catheterization. The product is described as an implantable therapy with patient-controlled activation and intended outpatient placement. The company was founded in 2025 and has raised a $2.073 million Seed round, indicating an early-stage profile rather than an established commercial-scale business. Its differentiation therefore rests on the targeted UAB indication, the proposed activation of the voiding neural circuit, and the research history behind the mechanism—not on verified comparative performance or commercial adoption.

Paxos Medical’s disclosed trajectory is that of an early-stage medical-device company moving from formation toward development of a focused implantable therapy. The company was founded in 2025 and announced a $2.073 million Seed round on May 8, 2026. Leadership appointments provide another sign of team formation: Jeff Erb is listed as CEO, Co-Founder, and Chairman; Matthew Fraser as CSO and Co-Founder; and Jon Ruais as COO, Co-Founder, and Board Member, with Ruais’s role beginning in April 2026. The central product initiative is UnderControl™, an implantable neuromodulation therapy intended to support voluntary voiding for people with underactive bladder. The company’s stated outpatient-placement and patient-controlled design goals suggest an emphasis on usability, but no launch date, regulatory milestone, clinical results, or hiring plan is specified. Further evidence of progress will depend on disclosed product, clinical, and regulatory milestones.